HOME >> BIOLOGY >> NEWS
Potential of tailoring drugs to genetic makeup confirmed--but challenges remain

At a time when harmful drug reactions are thought to rank just after strokes as a leading cause of death in the U.S., the potential benefits of tailoring drugs to a patients genetic makeup have been confirmed in a systematic study led by University of California, San Francisco scientists.

The quantitative assessment of the promise of this new approach known as pharmacogenomics confirms that many harmful drug reactions previously thought to be non-preventable may now actually be averted using genetic information about patients to select their drug therapies.

The study, the first systematic assessment of pharmacogenomics potential, is paired with an analysis of many remaining hurdles: questions about the effectiveness of the practice, inadequate training, funding and sites for carrying out patient genotyping; and the risk of creating inequities when developing drugs to avert problems caused by natural genetic differences linked to race.

The report appears in the November 14 issue of JAMA, the Journal of the American Medical Association.

The researchers first conducted two independent systematic literature reviews: one on studies reporting adverse drug reactions (ADRs) and one on studies reporting natural genetic variation, or variant alleles in genes for enzymes that metabolize drugs.

They then linked these two studies by focusing on the enzymes from the second search known to metabolize the drugs identified in the first search. This allowed them to assess the possible contribution of genetic variability to ADRs.

The results highlight a strong potential link between the genetic variants and adverse drug reactions. The scientists found that 59 percent of the drugs cited in the ADR study are metabolized by at least one enzyme with a naturally occurring variant known to cause poor metabolism.

Conversely, only 22 percent of randomly selected drugs sold in the U.S. and only 7 percent of randomly selected top-selling
'"/>

Contact: Wallace Ravven
wravven@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
13-Nov-2001


Page: 1 2 3

Related biology news :

1. Potential for enhanced sequestration of carbon in soils supports evaluations
2. Potential blood test for colon cancer risk
3. Potential new treatment for Gaucher disease developed by scientists at Scripps Research Institute
4. Potential cause of arthritis discovered
5. Potential of regenerative medicine explored
6. Potential therapy reported for children, adults with end-stage liver disease
7. Potential allergy vaccine boosts hope for sufferers
8. Potential new anthrax therapy discovered
9. Potential gene therapy carriers created that mimic viruses, without the risk
10. New Class Of Synthetic Capsules That Mimic Biological Cells Has Wide Array Of Potential Uses
11. Role Of Protein Linked To Colon Cancer Identified, Offering Potential Target For Therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/3/2020)... (PRWEB) , ... March 03, 2020 , ... Amplify Surgical, ... with the dualX Expanding Interbody Fusion System. , The landmark case was ... After the case Dr. Najafi noted, “dualX has completely changed the game for ...
(Date:3/2/2020)... ... March 02, 2020 , ... Rigaku Corporation is ... Chemistry and Applied Spectroscopy ( Pittcon 2020 ), being held March 1 - ... conference and exposition on laboratory science, attracting attendees from industry, academia and government ...
(Date:2/28/2020)... ... February 27, 2020 , ... ... has formed Filtravate, its newest portfolio company. Established to develop and commercialize ... exclusively licensed from New Mexico State University (NMSU). The patent-pending technology results ...
Breaking Biology News(10 mins):
(Date:3/27/2020)... ... March 25, 2020 , ... ... its veterinary histopathology laboratory located centrally in the midwest for high-quality, quick-turn, ... work with a highly motivated, independent, professional team that is focused on ...
(Date:3/12/2020)... ... 12, 2020 , ... With the beginning of 2020, Park ... investment in Europe by inaugurating a new scientific facility for academic and industrial ... Nanoscience Center Europe took place Tuesday, February 18, 2020, gathering customers, collaborators and ...
(Date:3/4/2020)... ... , ... This month, Cognosante will make its annual appearance at the HIMSS ... and emerging offerings that align with the HIMSS annual theme, “Be the Change.” ... and engaging. From Interoperability and HIE to Cloud Computing ...
(Date:2/26/2020)... , ... February 25, 2020 , ... ... & Biosciences (DuPont) recently published the results of its safety assessment on the ... HMOs currently identified in human milk. These complex carbohydrates are indigestible and therefore ...
Breaking Biology Technology:
Cached News: